Factors affecting repeated cessations of injecting drug use and relapses during the entire injecting career among the Edinburgh Addiction Cohort

Drug and Alcohol Dependence

Volumn 151, Issue , 2015, Pages 76-83

  Xia, Yang ^a   Seaman, Shaun ^a   Hickman, Matthew ^b   Macleod, John ^b   Robertson, Roy ^c,d   Copeland, Lorraine ^d   McKenzie, Jim ^d   De Angelis, Daniela ^a,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d Muirhouse Medical Group   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Cessation; Heroin addiction; Opiate substitution treatment; Random effects model; Recurrent events; Relapse

Indexed keywords

BUPRENORPHINE; DIHYDROCODEINE; METHADONE;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; INTRAVENOUS DRUG ABUSE; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; ADOLESCENT; BEHAVIOR, ADDICTIVE; CHILD; CHRONIC DISEASE; COMPLICATION; RECURRENT DISEASE; SCOTLAND; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; BEHAVIOR, ADDICTIVE; CHILD; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HUMANS; MALE; OPIATE SUBSTITUTION TREATMENT; RECURRENCE; SCOTLAND; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; YOUNG ADULT;

EID: 84929949898     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.03.005     Document Type: Article

References (56)

1. Aalen O.O., Borgan Ø, Gjessing H.K. Survival and Event History Analysis - A Process Point of View 2008, Springer.
2. Alter M., Moyer L. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 18:S6-10.
3. Amato L., Davoli M., Perucci C., Ferri M., Faggiano F., Mattick R. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 2005, 28:321-329.
4. Bargagli A., Hickman M., Davoli M., Perucci C., Schifano P., Buster M., et al. Drug-related mortality and its impact on adult mortality in eight European countries. Eur. J. Public Health 2006, 16:198-202.
5. Biernacki P. Pathways from Heroin Addiction: Recovery Without Treatment 1986, Temple University Press, Philadelphia.
6. Copeland L., Budd J., Elton R. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch. Intern. Med. 2004, 164:1214-1220.
7. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010, 341:c5475.
8. De Angelis D., Sweeting M., Ades A., Hickman M., Hope V., Ramsay M. An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales. Stat. Methods Med. Res. 2009, 18:361-379.
9. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M., et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2010, 106:32-51.
10. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010, 376:285-301.
11. Galai N., Safaeian M., Vlahov D., Bolotin A., Celentano D.D. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. Am. J. Epidemiol. 2003, 158:695-704.
12. Godfrey C., Eaton G. The economic and social costs of Class A drug use in England and Wales, 2000. Technical Report 2002, Home Office Research, Development and Statistics Directorate.
13. Godfrey C., Stewart D., Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: two year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004, 99:697-707.
14. Goldstein A., Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend. 1995, 40:139-150.
15. Gossop M., Trakada K., Stewart D., Witton J. Reductions in criminal convictions after addiction treatment: 5-year follow-up. Drug Alcohol Depend. 2005, 79:295-302.
16. Gowing L., Farrell M., Bornemann R., Sullivan L., Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Technical Report 8. Cochrane Database Syst. Rev. 2011.
17. Harding W., Zinberg N., Stelmack S., Barry M. Formerly-addicted-now-controlled opiate users. Int. J. Addict. 1980, 15:47-60.
18. Hser Y., Huang D., Chou C., Anglin M. Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study. Eval. Rev. 2007, 31:548-563.
19. Hser Y.I., Hoffman V., Grella C.E., Anglin M.D. A 33-year follow-up of narcotics addicts. Arch. Gen. Psychiatry 2001, 58:503-508.
20. Kimber J., Copeland L., Hickman M., Macleod J., McKenzie J., De Angelis D., Robertson J.R. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010, 341:c3172.
21. Langendam M.W., Van Brussel G.H.A., Coutinho R.A., Van Ameijden E.J.C. Methadone maintenance and cessation of injecting drug use: results from the Amsterdam Cohort Study. Addiction 2000, 95:591-600.
22. Macleod J., Copeland L., Hickman M., McKenzie J., Kimber J., De Angelis D., Robertson J.R. The Edinburgh Addiction Cohort: recruitment and follow-up of a primary care based sample of injection drug users and non drug-injecting controls. BMC Public Health 2010, 10:1-13. http://www.ncbi.nlm.nih.gov/pubmed/20187928.
23. Macleod J., Hickman M., Jones H.E., Copeland L., McKenzie J.S., De Angelis D. Early life influences on the risk of injecting drug use: case control study based on the Edinburgh Addiction Cohort. Addiction 2012, 108:743-750.
24. Maddux J., Desmond D. New light on the maturing out hypothesis in opioid dependence. Bull. Narc. 1980, 32:15-25.
25. Maddux J., Desmond D. Relapse and recovery in substance abuse careers. NIDA Res. Monogr. 1986, 72:49-71.
26. Mathers B., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R., et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-1028.
27. Mathers B., Degenhardt L., Wiessing L., Hickman M., Strathdee S., Wodak A., et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008, 372:1733-1745.
28. McLellan A., Lewis D., O'Brien C., Kleber H. Drug dependence, a chronic medical illness: implications for treatment, insurance and outcomes evaluation. JAMA 2000, 284:1689-1695.
29. Neuhaus J.M., Kalbfleisch J.D. Between- and within-cluster covariate effects in the analysis of clustered data. Biometrics 1998, 54:638-645.
30. Nosyk B., Anglin M.D., Brecht M.L., Lima V.D., Hser Y.I. Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study. Am. J. Epidemiol. 2013, 177:675-682.
31. O'Brien C.P. Addiction and dependence in DSM-V. Addiction 2011, 106:866-867.
32. O'Brien C.P., McLellan A.T. Myths about the treatment of addiction. Lancet 1996, 347:237-240.
33. R Core Team R: A Language and Environment for Statistical Computing 2014, R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
34. Rathod N., Addenbrooke W., Rosenbach A. Heroin dependence in an English town: 33-year follow-up. Br. J. Psychiatry 2005, 187:421-425.
35. Robbins L., Helzer J., Davies D.H. Narcotic use in southeast-Asia and afterward - interview study of 898 Vietnam returnees. Arch. Gen. Psychiatry 1975, 32:955-961.
36. Robertson J., Bucknall A., Welsby P., Roberts J., Inglis J., Peutherer J., Brettle R. Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers. BMJ 1986, 292:527-529.
37. Robertson J.R., Raab G.M., Bruce M., McKenzie J.S., Storkey H.R., Salter A. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence. A randomized controlled trial. Addiction 2006, 101:1752-1759.
38. Robertson J.R., Ronald P.J., Raab G.M., Ross A.J., Parpia T. Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years. BMJ 1994, 309:369-372.
39. Robertson R., Richardson A. Heroin injecting and the introduction of HIV/AIDS into a Scottish city. J. R. Soc. Med. 2007, 100:491-494.
40. Seaman S., Pavlou M., Copas A. Review of methods for handling confounding by cluster and informative cluster size in clustered data. Stat. Med. 2014, 33:5371-5387.
41. Shah N.G., Galai N., Celentano D.D., Vlahov D., Strathdee S.A. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend. 2006, 83:147-156. 10.1016/j.drugalcdep.2005.11.007.
42. Skidmore C.A., Robertson J.R., Robertson A.A., Elton R.A. After the epidemic: follow up study of HIV seroprevalence and changing patterns of drug use. BMJ 1990, 300:219-223.
43. StataCorp Stata Statistical Software: Release 11 2009, StataCorp LP, College Station, TX.
44. Stimson G., Oppenheimer E. Heroin Addiction: Treatment and Control in Britain 1982, Tavistock, London.
45. Sweeting M., De Angelis D., Ades A., Hickman M. Estimating the prevalence of ex-injecting drug use in the population. Stat. Methods Med. Res. 2009, 18:381-395.
46. Termorshuizen F., Krol A., Prins M., van Ameijden E.J.C. Long-term outcome of chronic drug use: The Amsterdam Cohort Study among drug users. Am. J. Epidemiol. 2005, 161:271-279.
47. Termorshuizen F., Krol A., Prins M., Geskus R., van den Brink W., van Ameijden E.J.C. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend. 2005, 79:231-240.
48. Therneau T. coxme: Mixed Effects Cox Models 2012, http://CRAN.R-project.org/package=coxme.
49. Turner K., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011, 106:1978-1988.
50. Vaillant G. A 20-year follow-up of New York nacotic addicts. Arch. Gen. Psychiatry 1973, 29:237-241.
51. van den Berg C., van Brussel G., Coutinho R.M.P. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102:1454-1462.
52. Vlahov D., Anthony J., Munoz A., Margolick J., Nelson K., Celentano D., et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res. Monogr. 1991, 109:75-100.
53. Winick C. Maturing out of narcotic addiction. Bull. Narc. 1962, 14:1-7.
54. Winick C. The life cycle of the narcotic addict and of addiction. Bull. Narc. 1964, 16:1-11.
55. Xia Y. Characterising Patterns of Injecting Drug Use 2013, University of Cambridge, Cambridge, United Kingdom, (Ph.D. thesis).
56. Zinberg N., Jacobson R. The natural history of chipping. Am. J. Psychiatry 1976, 133:37-40.